Quantcast
Home > Quotes > FTSV
x

Forty Seven, Inc. Common Stock (FTSV) Quote & Summary Data

FTSV 
$14.13
*  
0.16
1.12%
Get FTSV Alerts
*Delayed - data as of Oct. 18, 2018 13:37 ET  -  Find a broker to begin trading FTSV now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    FTSV Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 13.93 / $ 14.33
1 Year Target
26
Today's High / Low
$ 14.31 / $ 13.80
Share Volume
17,571
50 Day Avg. Daily Volume
96,748
Previous Close
$ 14.29
52 Week High / Low
$ 16.86 / $ 12.16
Market Cap
438,709,455
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0

Intraday Chart

News for FTSV

Shares Traded

Share Volume:
17,571
50 Day Avg. Daily Volume:
96,748

Trading Range

The current last sale of $14.13 is 16.20% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 14.31 $ 16.86
 Low: $ 13.80 $ 12.16

Company Description (as filed with the SEC)

We are a clinical-stage immuno-oncology company focused on developing novel checkpoint therapies to activate macrophages in the fight against cancer. We founded Forty Seven based on the insight that blocking CD47, a key signaling molecule that is overexpressed on cancer cells, renders tumors susceptible to macrophages. By harnessing macrophages, we believe that our lead product candidate, 5F9, dosed as a monotherapy or in combination with marketed cancer therapies, can transform the treatment of cancer. 5F9 has demonstrated promising activity in six Phase 1b/2 clinical trials in which we have treated over 190 relapsed or refractory cancer patients with solid or hematologic tumors. We hold worldwide rights to all of our product candidates. We focus our efforts on targeting the CD47 pathway as a way to engage macrophages in fighting tumors.  ... More ...  


Risk Grade

Where does FTSV fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 14.31
Open Date:
Oct. 18, 2018
Close Price:
$ 14.29
Close Date:
Oct. 17, 2018

Consensus Recommendation

Analyst Info